SGLT+Paper_mymindcirculation_10Refs++26072018_Final_.pdf (271.68 kB)
Download file

Should sodium glucose co-transporter 2 inhibitors be considered as first line oral therapy for people with type 2 diabetes?

Download (271.68 kB)
journal contribution
posted on 27.09.2018, 08:39 by Kamlesh Khunti, Samuel Seidu, Melanie J. Davies
Type 2 diabetes mellitus (T2DM) is a chronic condition associated with long-term microvascular and macrovascular complications. Evidence-based guidelines recommend the individualisation of therapies to manage hyperglycaemia in order to reduce risk of complications.

Funding

This article is based on an invited oral symposium presentation at the Diabetes UK Professional Conference in London in March 2018. KK acknowledge the support from National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care – East Midlands (NIHR CLAHRC – EM) and the NIHR Leicester, Biomedical Research Centre.

History

Citation

Diabetes, Obesity and Metabolism, 2018

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Diabetes Research Centre

Version

AM (Accepted Manuscript)

Published in

Diabetes

Publisher

Wiley

issn

1462-8902

eissn

1463-1326

Acceptance date

29/08/2018

Copyright date

2018

Available date

03/09/2019

Publisher version

https://onlinelibrary.wiley.com/doi/abs/10.1111/dom.13518

Notes

The file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.

Language

en

Usage metrics

Categories

Keywords

Exports